Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 81 | ECE2022 | Next issue

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

Card image cap
The 24th European Congress of Endocrinology (ECE) and the Italian Society of Endocrinology look forward to welcoming you to Milan. ECE 2022 returns for a four day, six parallel session festival of endocrine science. You can join us In person in Milan, Italy OR Live @Home online!

Oral Communications

Oral Communications 6: Endocrine-Related Cancer

ea0081oc6.1 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma

Li Minghao , Prodanov Tamara , Meuter Leah , Kerstens Michiel , Bechmann Nicole , Prejbisz Aleksander , Fassnacht Martin , Timmers Henri , Beuschlein Felix , Fliedner Stephanie , Robledo Mercedes , Lenders Jacques , Pacak Karel , Eisenhofer Graeme , Pamporaki Christina

Background: It is well established that life-long follow-up is required for patients with hereditary pheochromocytomas and paragangliomas (PPGLs), due to the potential of developing recurrent disease. However, whether follow-up of patients with sporadic PPGLs is necessary, remains unclear.Aims: To examine the prevalence and predictors of recurrent disease in patients with sporadic PPGLs.Materials and method: This multicenter study included retrospective ...

ea0081oc6.2 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Translational evidence for splicing factor RBM22 as a novel prognostic biomarker and therapeutic target in prostate cancer

Saez-Martinez Prudencio , Jimenez-Vacas Juan M , Montero-Hidalgo Antonio J , Rosa-Herencia Ana D , Herrero-Aguayo Vicente , Leon-Gonzalez Antonio J , Sanchez-Sanchez Rafael , Gonzalez-Serrano Teresa , Gomez-Gomez Enrique , Gahete Manuel D , Luque Raul M

Prostate cancer (PCa) is one the leading causes of cancer-related deaths among men in developed countries. Therefore, identification of novel molecular and therapeutic approaches to tackle this pathology are urgently needed. In this scenario, our group has recently reported that elements of the cellular machinery controlling alternative splicing processes might be used as potential novel therapeutic tools against PCa and castration-resistant PCa (CRPC). In this context, RBM22 ...

ea0081oc6.3 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Systematic detection of mosaicism by using digital NGS in a cohort of 119 unresolved MEN1 cases reveals 3 new MEN1 mosaicisms

Lagarde Arnaud , Mougel Gregory , Coppin Lucie , Haissaguerre Magalie , Le Collen Lauriane , Klein Marc , Odou Marie-Francoise , Tabarin Antoine , Brixi Hedia , Delemer Brigitte , Barlier Anne , Romanet Pauline

Context: Mosaicism is a feature of several inherited tumor syndromes but is rarely systematically looked for in routine. MEN1 is an autosomal dominant hereditary syndrome characterized by several endocrine tumors affecting parathyroids, pancreas, and anterior pituitary most of the time, due to inactivating mutations in the MEN1 gene. Few cases of mosaicism in Multiple Endocrine Neoplasia type 1 (MEN1) have been described. MEN1 mosaicism is probably under-diag...

ea0081oc6.4 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Clinical correlates of a large Israeli cohort of Cys 618 Arg RET mutation

Chava Rosenblum Rachel , Hirsch Dania , Glasberg Simona , Benbassat Carlos , Yoel Uri , Ishay Avraham , Lamprecht Sagit Zolotov , Bachar Gideon , Banne Ehud , Twito Orit

Introduction: A syndrome of MEN2A and HirschsprungÂ’s disease described in Israeli Jews of Moroccan descent is caused by Cys 618 Arg mutation, one of the less common causes of MEN2A. We aimed to define the clinical characteristics of a large cohort with this mutation from a multi-center Israeli registry.Methods: The Israeli MTC registry including 8 centers was searched retrospectively for results of RET mutational analysis. Patients with a Cys 618 Ar...

ea0081oc6.5 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Antagonist of growth hormone-releasing hormone (GHRH) potentiates the antitumor effect of chemotherapy in human malignant pleural mesothelioma

Gesmundo Iacopo , Vitale Nicoletta , Orlando Giulia , Bertoldo Alessia , Papotti Mauro , Deaglio Silvia , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Human malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm, arising from pleural mesothelial cells, generally due exposure to asbestos. Of note, different growth factors and their receptors are involved in the pathogenesis of MPM and resistance to therapy. Chemotherapy with cisplatin (cis) and antifolates, like pemetrexed (PEM), is the first-line treatment for inoperable MPM. Growth hormone-releasing hormone (GHRH), besides stimulating GH secretion in the ant...

ea0081oc6.6 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1-splicing and mTOR/ß-catenin pathways imbalances

G-Garcia Miguel E , Fuentes-Fayos Antonio C , Gomez Jesus Perez , Jimenez-Vacas Juan M , Blanco-Acevedo Cristobal , Sanchez-Sanchez Rafael , Solivera Juan , Breunig Joshua , Gahete Manuel D , Castano Justo P , Luque Raul M

Glioblastoma (GBM; grade IV astrocytoma) is one of the most devastating endocrine-related cancer worldwide based on its locally aggressive behavior and because it cannot be cured by current therapies. Therefore, the identification of novel diagnostic and prognostic biomarkers, and especially efficient therapeutic targets is urgently needed. In this sense, defects in alternative splicing process are associated with poor survival and high aggressiveness in cancer, including GBM....